Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
BioJapan 2008

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 10 July 1987:
Vol. 237. no. 4811, pp. 178 - 182
DOI: 10.1126/science.2885917
Prev | Table of Contents | Next

Articles

Science, Vol 237, Issue 4811, 178-182
Copyright © 1987 by American Association for the Advancement of Science

articles

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells

PP Di Fiore, JH Pierce, MH Kraus, O Segatto, CR King, and SA Aaronson

A wide variety of human tumors contain an amplified or overexpressed erbB-2 gene, which encodes a growth factor receptor-like protein. When erbB-2 complementary DNA was expressed in NIH/3T3 cells under the control of the SV40 promoter, the gene lacked transforming activity despite expression of detectable levels of the erbB-2 protein. A further five- to tenfold increase in its expression under influence of the long terminal repeat of Moloney murine leukemia virus was associated with activation of erbB-2 as a potent oncogene. The high levels of the erbB-2 product associated with malignant transformation of NIH/3T3 cells were observed in human mammary tumor cells that overexpressed this gene. These findings demonstrate a new mechanism for acquisition of oncogenic properties by genes encoding growth factor receptor-like proteins and provide a functional basis for the role of their overexpression in the development of human malignancies.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
TCR Gene Therapy of Spontaneous Prostate Carcinoma Requires In Vivo T Cell Activation.
M. A. de Witte, G. M. Bendle, M. D. van den Boom, M. Coccoris, T. D. Schell, S. S. Tevethia, H. van Tinteren, E. M. Mesman, J.-Y. Song, and T. N. M. Schumacher (2008)
J. Immunol. 181, 2563-2571
   Abstract »    Full Text »    PDF »
Quantitative Characterization of the Large-Scale Association of ErbB1 and ErbB2 by Flow Cytometric Homo-FRET Measurements.
A. Szabo, G. Horvath, J. Szollosi, and P. Nagy (2008)
Biophys. J. 95, 2086-2096
   Abstract »    Full Text »    PDF »
GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation.
T. Bai and S.-W. Luoh (2008)
Carcinogenesis 29, 473-479
   Abstract »    Full Text »    PDF »
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer.
L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr (2007)
J. Clin. Oncol. 25, 5287-5312
   Abstract »    Full Text »    PDF »
In vivo Diagnosis of Epidermal Growth Factor Receptor Expression using Molecular Imaging with a Cocktail of Optically Labeled Monoclonal Antibodies.
T. Barrett, Y. Koyama, Y. Hama, G. Ravizzini, I. S. Shin, B.-S. Jang, C. H. Paik, Y. Urano, P. L. Choyke, and H. Kobayashi (2007)
Clin. Cancer Res. 13, 6639-6648
   Abstract »    Full Text »    PDF »
Discovery and Pharmacologic Characterization of CP-724,714, a Selective ErbB2 Tyrosine Kinase Inhibitor.
J. P. Jani, R. S. Finn, M. Campbell, K. G. Coleman, R. D. Connell, N. Currier, E. O. Emerson, E. Floyd, S. Harriman, J. C. Kath, et al. (2007)
Cancer Res. 67, 9887-9893
   Abstract »    Full Text »    PDF »
Spectral Fluorescence Molecular Imaging of Lung Metastases Targeting HER2/neu.
Y. Koyama, Y. Hama, Y. Urano, D. M. Nguyen, P. L. Choyke, and H. Kobayashi (2007)
Clin. Cancer Res. 13, 2936-2945
   Abstract »    Full Text »    PDF »
Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node-positive patients.
H. Kim, T. Yoo, D. Park, J. Park, Y. Cho, C. Sohn, W. Jeon, B. Kim, M. Kim, S. Chae, et al. (2007)
Ann. Onc. 18, 892-897
   Abstract »    Full Text »    PDF »
The Tumor Suppressor Activity of the Lysyl Oxidase Propeptide Reverses the Invasive Phenotype of Her-2/neu-Driven Breast Cancer.
C. Min, K. H. Kirsch, Y. Zhao, S. Jeay, A. H. Palamakumbura, P. C. Trackman, and G. E. Sonenshein (2007)
Cancer Res. 67, 1105-1112
   Abstract »    Full Text »    PDF »
Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy..
F. Meric-Bernstam and M.-C. Hung (2006)
Clin. Cancer Res. 12, 6326-6330
   Abstract »    Full Text »    PDF »
Non-Small-Cell Lung Cancer and Ba/F3 Transformed Cells Harboring the ERBB2 G776insV_G/C Mutation Are Sensitive to the Dual-Specific Epidermal Growth Factor Receptor and ERBB2 Inhibitor HKI-272..
T. Shimamura, H. Ji, Y. Minami, R. K. Thomas, A. M. Lowell, K. Shah, H. Greulich, K. A. Glatt, M. Meyerson, G. I. Shapiro, et al. (2006)
Cancer Res. 66, 6487-6491
   Abstract »    Full Text »    PDF »
Phosphoproteomic analysis of Her2/neu signaling and inhibition.
R. Bose, H. Molina, A. S. Patterson, J. K. Bitok, B. Periaswamy, J. S. Bader, A. Pandey, and P. A. Cole (2006)
PNAS 103, 9773-9778
   Abstract »    Full Text »    PDF »
Impact of IGF-I and CYP19 Gene Polymorphisms on the Survival of Patients With Metastatic Prostate Cancer.
N. Tsuchiya, L. Wang, H. Suzuki, T. Segawa, H. Fukuda, S. Narita, M. Shimbo, T. Kamoto, K. Mitsumori, T. Ichikawa, et al. (2006)
J. Clin. Oncol. 24, 1982-1989
   Abstract »    Full Text »    PDF »
A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease.
P. Papaldo, A. Fabi, G. Ferretti, M. Mottolese, A. M. Cianciulli, B. Di Cocco, M. S. Pino, P. Carlini, S. Di Cosimo, I. Sacchi, et al. (2006)
Ann. Onc. 17, 630-636
   Abstract »    Full Text »    PDF »
Role of exon-16-deleted HER2 in breast carcinomas..
F Castiglioni, E Tagliabue, M Campiglio, S M Pupa, A Balsari, and S Menard (2006)
Endocr. Relat. Cancer 13, 221-232
   Abstract »    Full Text »    PDF »
p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer.
R. Saez, M. A. Molina, E. E. Ramsey, F. Rojo, E. J. Keenan, J. Albanell, A. Lluch, J. Garcia-Conde, J. Baselga, and G. M. Clinton (2006)
Clin. Cancer Res. 12, 424-431
   Abstract »    Full Text »    PDF »
Caveolin-1 Deficiency (-/-) Conveys Premalignant Alterations in Mammary Epithelia, with Abnormal Lumen Formation, Growth Factor Independence, and Cell Invasiveness.
F. Sotgia, T. M. Williams, W. Schubert, F. Medina, C. Minetti, R. G. Pestell, and M. P. Lisanti (2006)
Am. J. Pathol. 168, 292-309
   Abstract »    Full Text »    PDF »
The Inhibitory Effect of ErbB2 on Epidermal Growth Factor-induced Formation of Clathrin-coated Pits Correlates with Retention of Epidermal Growth Factor Receptor-ErbB2 Oligomeric Complexes at the Plasma Membrane.
C. Haslekas, K. Breen, K. W. Pedersen, L. E. Johannessen, E. Stang, and I. H. Madshus (2005)
Mol. Biol. Cell 16, 5832-5842
   Abstract »    Full Text »    PDF »
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer..
M. J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, et al. (2005)
N. Engl. J. Med. 353, 1659-1672
   Abstract »    Full Text »    PDF »
Activation of ErbB2 by Overexpression or by Transmembrane Neuregulin Results in Differential Signaling and Sensitivity to Herceptin.
L. Yuste, J. C. Montero, A. Esparis-Ogando, and A. Pandiella (2005)
Cancer Res. 65, 6801-6810
   Abstract »    Full Text »    PDF »
ERBB2 in Pediatric Cancer: Innocent Until Proven Guilty.
R. J. Gilbertson (2005)
Oncologist 10, 508-517
   Abstract »    Full Text »    PDF »
The epidermal growth factor receptor family.
L A Bazley and W J Gullick (2005)
Endocr. Relat. Cancer 12, S17-S27
   Abstract »    Full Text »    PDF »
Low Levels of Her2/neu Expressed by Ewing's Family Tumor Cell Lines Can Redirect Cytokine-Induced Killer Cells.
M. R. Verneris, A. Arshi, M. Edinger, M. Kornacker, Y. Natkunam, M. Karami, Y.-a. Cao, N. Marina, C. H. Contag, and R. S. Negrin (2005)
Clin. Cancer Res. 11, 4561-4570
   Abstract »    Full Text »    PDF »
Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor.
D. McKillop, E. A. Partridge, J. V. Kemp, M. P. Spence, J. Kendrew, S. Barnett, P. G. Wood, P. B. Giles, A. B. Patterson, F. Bichat, et al. (2005)
Mol. Cancer Ther. 4, 641-649
   Abstract »    Full Text »    PDF »
Oligomers of ERBB3 Have Two Distinct Interfaces That Differ in Their Sensitivity to Disruption by Heregulin.
K. Kani, C. M. Warren, C. S. Kaddis, J. A. Loo, and R. Landgraf (2005)
J. Biol. Chem. 280, 8238-8247
   Abstract »    Full Text »    PDF »
Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (HerceptinTM) in breast cancer cells with Her-2/neu oncogene amplification.
J. A. Menendez, L. Vellon, R. Colomer, and R. Lupu (2005)
Ann. Onc. 16, 359-371
   Abstract »    Full Text »    PDF »
The Roles of Versican V1 and V2 Isoforms in Cell Proliferation and Apoptosis.
W. Sheng, G. Wang, Y. Wang, J. Liang, J. Wen, P.-S. Zheng, Y. Wu, V. Lee, J. Slingerland, D. Dumont, et al. (2005)
Mol. Biol. Cell 16, 1330-1340
   Abstract »    Full Text »    PDF »
Gefitinib ("Iressa", ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses Breast Cancer Resistance Protein/ABCG2-Mediated Drug Resistance.
Y. Nakamura, M. Oka, H. Soda, K. Shiozawa, M. Yoshikawa, A. Itoh, Y. Ikegami, J. Tsurutani, K. Nakatomi, T. Kitazaki, et al. (2005)
Cancer Res. 65, 1541-1546
   Abstract »    Full Text »    PDF »
Decreased Accessibility and Lack of Activation of ErbB2 in JIMT-1, a Herceptin-Resistant, MUC4-Expressing Breast Cancer Cell Line.
P. Nagy, E. Friedlander, M. Tanner, A. I. Kapanen, K. L. Carraway, J. Isola, and T. M. Jovin (2005)
Cancer Res. 65, 473-482
   Abstract »    Full Text »    PDF »
Identification and validation of cell surface antigens for antibody targeting in oncology.
P. Carter, L. Smith, and M. Ryan (2004)
Endocr. Relat. Cancer 11, 659-687
   Abstract »    Full Text »    PDF »
Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin.
C. D. Austin, A. M. De Maziere, P. I. Pisacane, S. M. van Dijk, C. Eigenbrot, M. X. Sliwkowski, J. Klumperman, and R. H. Scheller (2004)
Mol. Biol. Cell 15, 5268-5282
   Abstract »    Full Text »    PDF »
ERBB2 Amplifications in Esophageal Adenocarcinoma.
P. S. Dahlberg, B. A. Jacobson, G. Dahal, J. M. Fink, R. A. Kratzke, M. A. Maddaus, and L. J. Ferrin (2004)
Ann. Thorac. Surg. 78, 1790-1800
   Abstract »    Full Text »    PDF »
Forkhead Box Transcription Factor FOXO3a Regulates Estrogen Receptor Alpha Expression and Is Repressed by the Her-2/neu/Phosphatidylinositol 3-Kinase/Akt Signaling Pathway.
S. Guo and G. E. Sonenshein (2004)
Mol. Cell. Biol. 24, 8681-8690
   Abstract »    Full Text »    PDF »
Her-2/neu Overexpression and Amplification in Uterine Papillary Serous Carcinoma.
B. M. Slomovitz, R. R. Broaddus, T. W. Burke, N. Sneige, P. T. Soliman, W. Wu, C. C. Sun, M. F. Munsell, D. M. Gershenson, and K. H. Lu (2004)
J. Clin. Oncol. 22, 3126-3132
   Abstract »    Full Text »    PDF »
An Integrated View of Copy Number and Allelic Alterations in the Cancer Genome Using Single Nucleotide Polymorphism Arrays.
X. Zhao, C. Li, J. G. Paez, K. Chin, P. A. Janne, T.-H. Chen, L. Girard, J. Minna, D. Christiani, C. Leo, et al. (2004)
Cancer Res. 64, 3060-3071
   Abstract »    Full Text »    PDF »
HIP1 and HIP1r Stabilize Receptor Tyrosine Kinases and Bind 3-Phosphoinositides via Epsin N-terminal Homology Domains.
T. S. Hyun, D. S. Rao, D. Saint-Dic, L. E. Michael, P. D. Kumar, S. V. Bradley, I. F. Mizukami, K. I. Oravecz-Wilson, and T. S. Ross (2004)
J. Biol. Chem. 279, 14294-14306
   Abstract »    Full Text »    PDF »
Blockade of Epidermal Growth Factor- or Heregulin-Dependent ErbB2 Activation with the Anti-ErbB2 Monoclonal Antibody 2C4 Has Divergent Downstream Signaling and Growth Effects.
J. G. Jackson, P. St. Clair, M. X. Sliwkowski, and M. G. Brattain (2004)
Cancer Res. 64, 2601-2609
   Abstract »    Full Text »    PDF »
Ligand-induced, p38-dependent Apoptosis in Cells Expressing High Levels of Epidermal Growth Factor Receptor and ErbB-2.
O. Tikhomirov and G. Carpenter (2004)
J. Biol. Chem. 279, 12988-12996
   Abstract »    Full Text »    PDF »
Clinical, Histopathologic, and Molecular Markers of Prognosis: Toward a New Disease Risk Stratification System for Medulloblastoma.
A. Gajjar, R. Hernan, M. Kocak, C. Fuller, Y. Lee, P. J. McKinnon, D. Wallace, C. Lau, M. Chintagumpala, D. M. Ashley, et al. (2004)
J. Clin. Oncol. 22, 984-993
   Abstract »    Full Text »    PDF »
Cooperation of the ErbB2 receptor and transforming growth factor {beta} in induction of migration and invasion in mammary epithelial cells.
S. E. Seton-Rogers, Y. Lu, L. M. Hines, M. Koundinya, J. LaBaer, S. K. Muthuswamy, and J. S. Brugge (2004)
PNAS 101, 1257-1262
   Abstract »    Full Text »    PDF »
Her2-neu: a target in lung cancer?.
F. Andre, T. Le Chevalier, and J. C. Soria (2004)
Ann. Onc. 15, 3-4
   Full Text »    PDF »
Combining trastuzumab (Herceptin(R)) with hormonal therapy in breast cancer: what can be expected and why?.
A. Jones (2003)
Ann. Onc. 14, 1697-1704
   Abstract »    Full Text »    PDF »
Gene Amplification in Esophageal Adenocarcinomas and Barrett's with High-Grade Dysplasia.
C. T. Miller, J. R. Moy, L. Lin, M. Schipper, D. Normolle, D. E. Brenner, M. D. Iannettoni, M. B. Orringer, and D. G. Beer (2003)
Clin. Cancer Res. 9, 4819-4825
   Abstract »    Full Text »    PDF »
HER2-Mediated Effects on EGFR Endosomal Sorting: Analysis of Biophysical Mechanisms.
B. S. Hendriks, H. S. Wiley, and D. Lauffenburger (2003)
Biophys. J. 85, 2732-2745
   Abstract »    Full Text »    PDF »
Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer.
G. Atalay, F. Cardoso, A. Awada, and M. J. Piccart (2003)
Ann. Onc. 14, 1346-1363
   Abstract »    Full Text »    PDF »
Medulloblastoma Sensitivity to 17-Allylamino-17-demethoxygeldanamycin Requires MEK/ERK.
C. Calabrese, A. Frank, K. Maclean, and R. Gilbertson (2003)
J. Biol. Chem. 278, 24951-24959
   Abstract »    Full Text »    PDF »
Quantitative Analysis of HER2-mediated Effects on HER2 and Epidermal Growth Factor Receptor Endocytosis: DISTRIBUTION OF HOMO- AND HETERODIMERS DEPENDS ON RELATIVE HER2 LEVELS.
B. S. Hendriks, L. K. Opresko, H. S. Wiley, and D. Lauffenburger (2003)
J. Biol. Chem. 278, 23343-23351
   Abstract »    Full Text »    PDF »
Association of 17q21-q24 Gain in Ovarian Clear Cell Adenocarcinomas with Poor Prognosis and Identification of PPM1D and APPBP2 as Likely Amplification Targets.
A. Hirasawa, F. Saito-Ohara, J. Inoue, D. Aoki, N. Susumu, T. Yokoyama, S. Nozawa, J. Inazawa, and I. Imoto (2003)
Clin. Cancer Res. 9, 1995-2004
   Abstract »    Full Text »    PDF »
Beyond Radioiodine: A Review of Potential New Therapeutic Approaches for Thyroid Cancer.
M. Braga-Basaria and M. D. Ringel (2003)
J. Clin. Endocrinol. Metab. 88, 1947-1960
   Abstract »    Full Text »    PDF »
Coregulation of Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor 2 (HER2) Levels and Locations: Quantitative Analysis of HER2 Overexpression Effects.
B. S. Hendriks, L. K. Opresko, H. S. Wiley, and D. Lauffenburger (2003)
Cancer Res. 63, 1130-1137
   Abstract »    Full Text »    PDF »
A Chimeric Humanized Single-Chain Antibody against the Type I Insulin-like Growth Factor (IGF) Receptor Renders Breast Cancer Cells Refractory to the Mitogenic Effects of IGF-I.
D. Sachdev, S.-L. Li, J. S. Hartell, Y. Fujita-Yamaguchi, J. S. Miller, and D. Yee (2003)
Cancer Res. 63, 627-635
   Abstract »    Full Text »    PDF »
Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention.
R. Nahta, G. N. Hortobagyi, and F. J. Esteva (2003)
Oncologist 8, 5-17
   Abstract »    Full Text »    PDF »
Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology Group.
M. A. Bookman, K. M. Darcy, D. Clarke-Pearson, R. A. Boothby, and I. R. Horowitz (2003)
J. Clin. Oncol. 21, 283-290
   Abstract »    Full Text »    PDF »
Identification of ErbB-2 Kinase Domain Motifs Required for Geldanamycin-induced Degradation.
O. Tikhomirov and G. Carpenter (2003)
Cancer Res. 63, 39-43
   Abstract »    Full Text »    PDF »
ERBB2 Up-Regulates S100A4 and Several other Prometastatic Genes in Medulloblastoma.
R. Hernan, R. Fasheh, C. Calabrese, A. J. Frank, K. H. Maclean, D. Allard, R. Barraclough, and R. J. Gilbertson (2003)
Cancer Res. 63, 140-148
   Abstract »    Full Text »    PDF »
Signaling Initiated by Overexpression of the Fibroblast Growth Factor Receptor-1 Investigated by Mass Spectrometry.
A. M. Hinsby, J. V. Olsen, K. L. Bennett, and M. Mann (2003)
Mol. Cell. Proteomics 2, 29-36
   Abstract »    Full Text »    PDF »
Active Signaling by HER-2/neu in a Subpopulation of HER-2/neu-overexpressing Ductal Carcinoma in Situ: Clinicopathological Correlates.
M. P. DiGiovanna, P. Chu, T. L. Davison, C. L. Howe, D. Carter, E. B. Claus, and D. F. Stern (2002)
Cancer Res. 62, 6667-6673
   Abstract »    Full Text »    PDF »
Differential Regulation of Tumor Angiogenesis by Distinct ErbB Homo- and Heterodimers.
L. Yen, N. Benlimame, Z.-R. Nie, D. Xiao, T. Wang, A.-E. A. Moustafa, H. Esumi, J. Milanini, N. E. Hynes, G. Pages, et al. (2002)
Mol. Biol. Cell 13, 4029-4044
   Abstract »    Full Text »    PDF »
Csk Homologous Kinase (CHK) and ErbB-2 Interactions Are Directly Coupled with CHK Negative Growth Regulatory Function in Breast Cancer.
S. Kim, R. Zagozdzon, A. Meisler, J. D. Baleja, Y. Fu, S. Avraham, and H. Avraham (2002)
J. Biol. Chem. 277, 36465-36470
   Abstract »    Full Text »    PDF »
Basolateral Targeting of ERBB2 Is Dependent on a Novel Bipartite Juxtamembrane Sorting Signal but Independent of the C-Terminal ERBIN-Binding Domain.
C. Dillon, A. Creer, K. Kerr, A. Kumin, and C. Dickson (2002)
Mol. Cell. Biol. 22, 6553-6563
   Abstract »    Full Text »    PDF »
Identification of a Region within the ErbB2/HER2 Intracellular Domain That Is Necessary for Ligand-independent Association.
E. Penuel, R. W. Akita, and M. X. Sliwkowski (2002)
J. Biol. Chem. 277, 28468-28473
   Abstract »    Full Text »    PDF »
Evaluation of HER-2/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens.
M. F. Press, D. J. Slamon, K. J. Flom, J. Park, J.-Y. Zhou, and L. Bernstein (2002)
J. Clin. Oncol. 20, 3095-3105
   Abstract »    Full Text »    PDF »
A Ligand-inducible Epidermal Growth Factor Receptor/Anaplastic Lymphoma Kinase Chimera Promotes Mitogenesis and Transforming Properties in 3T3 Cells.
G. Piccinini, R. Bacchiocchi, M. Serresi, C. Vivani, S. Rossetti, C. Gennaretti, D. Carbonari, and F. Fazioli (2002)
J. Biol. Chem. 277, 22231-22239
   Abstract »    Full Text »    PDF »
Targeting Multiple Her-2 Epitopes with Monoclonal Antibodies Results in Improved Antigrowth Activity of a Human Breast Cancer Cell Line in Vitro and in Vivo.
C. I. Spiridon, M.-A. Ghetie, J. Uhr, R. Marches, J.-L. Li, G.-L. Shen, and E. S. Vitetta (2002)
Clin. Cancer Res. 8, 1720-1730
   Abstract »    Full Text »    PDF »
Autocrine-mediated Activation of STAT3 Correlates with Cell Proliferation in Breast Carcinoma Lines.
L. Li and P. E. Shaw (2002)
J. Biol. Chem. 277, 17397-17405
   Abstract »    Full Text »    PDF »
Receptor tyrosine kinase, EphB4 (HTK), accelerates differentiation of select human hematopoietic cells.
Z. Wang, N. Miura, A. Bonelli, P. Mole, N. Carlesso, D. P. Olson, and D. T. Scadden (2002)
Blood 99, 2740-2747
   Abstract »    Full Text »    PDF »
Clinical effectiveness of trastuzumab: early experience.
C. Chambers, D. M. Dimaculangan, K. Grindrod, J. Hanson, F. Pataky, and T. T. Vu (2002)
Journal of Oncology Pharmacy Practice 8, 19-25
   Abstract »    PDF »
NH2-terminal Truncated HER-2 Protein but not Full-Length Receptor Is Associated with Nodal Metastasis in Human Breast Cancer.
M. A. Molina, R. Saez, E. E. Ramsey, M.-J. Garcia-Barchino, F. Rojo, A. J. Evans, J. Albanell, E. J. Keenan, A. Lluch, J. Garcia-Conde, et al. (2002)
Clin. Cancer Res. 8, 347-353
   Abstract »    Full Text »    PDF »
Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition.
J. Albanell, F. Rojo, S. Averbuch, A. Feyereislova, J. M. Mascaro, R. Herbst, P. LoRusso, D. Rischin, S. Sauleda, J. Gee, et al. (2002)
J. Clin. Oncol. 20, 110-124
   Abstract »    Full Text »    PDF »
A Case with HER2-overexpressing Breast Cancer Completely Responded to Humanized anti-HER2 Monoclonal Antibody.
M. Ohta, Y. Tokuda, Y. Suzuki, M. Kubota, T. Watanabe, H. Fujii, Y. Sasaki, T. Niwa, H. Makuuchi, and T. Tajima (2001)
Jpn. J. Clin. Oncol. 31, 553-556
   Abstract »    Full Text »    PDF »
Significance of, and Optimal Screening for, HER-2 Gene Amplification and Protein Overexpression in Breast Carcinoma.
W. K. Funkhouser and K. Kaiser-Rogers (2001)
Ann. Clin. Lab. Sci. 31, 349-358
   Abstract »    Full Text »    PDF »
Trastuzumab (Herceptin), a Humanized Anti-HER2 Receptor Monoclonal Antibody, Inhibits Basal and Activated HER2 Ectodomain Cleavage in Breast Cancer Cells.
M. A. Molina, J. Codony-Servat, J. Albanell, F. Rojo, J. Arribas, and J. Baselga (2001)
Cancer Res. 61, 4744-4749
   Abstract »    Full Text »    PDF »
Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification.
A. D. Seidman, M. N. Fornier, F. J. Esteva, L. Tan, S. Kaptain, A. Bach, K. S. Panageas, C. Arroyo, V. Valero, V. Currie, et al. (2001)
J. Clin. Oncol. 19, 2587-2595
   Abstract »    Full Text »    PDF »
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2.
D. J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, et al. (2001)
N. Engl. J. Med. 344, 783-792
   Abstract »    Full Text »    PDF »
DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice.
S. Rovero, A. Amici, E. D. Carlo, R. Bei, P. Nanni, E. Quaglino, P. Porcedda, K. Boggio, A. Smorlesi, P.-L. Lollini, et al. (2000)
J. Immunol. 165, 5133-5142
   Abstract »    Full Text »    PDF »
Inhibition of ErbB-2 Mitogenic and Transforming Activity by RALT, a Mitogen-Induced Signal Transducer Which Binds to the ErbB-2 Kinase Domain.
L. Fiorentino, C. Pertica, M. Fiorini, C. Talora, M. Crescenzi, L. Castellani, S. Alemà, P. Benedetti, and O. Segatto (2000)
Mol. Cell. Biol. 20, 7735-7750
   Abstract »    Full Text »
Generation of Tumor-Reactive CTL Against the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells Derived from CD34+ Hemopoietic Progenitor Cells.
C. Meyer zum Buschenfelde, N. Nicklisch, S. Rose-John, C. Peschel, and H. Bernhard (2000)
J. Immunol. 165, 4133-4140
   Abstract »    Full Text »    PDF »
Activation (Tyrosine Phosphorylation) of ErbB-2 (HER-2/neu): A Study of Incidence and Correlation With Outcome in Breast Cancer.
A. D. Thor, S. Liu, S. Edgerton, D. Moore II, K. M. Kasowitz, C. C. Benz, D. F. Stern, and M. P. DiGiovanna (2000)
J. Clin. Oncol. 18, 3230-3239
   Abstract »    Full Text »    PDF »
Both Src-Dependent and -Independent Mechanisms Mediate Phosphatidylinositol 3-Kinase Regulation of Colony-Stimulating Factor 1-Activated Mitogen-Activated Protein Kinases in Myeloid Progenitors.
A. W.-M. Lee and D. J. States (2000)
Mol. Cell. Biol. 20, 6779-6798
   Abstract »    Full Text »
Effects of c-erbB2 Overexpression on the Drug Sensitivities of Normal Human Mammary Epithelial Cells.
M. S. Orr, P. M. O'Connor, and K. W. Kohn (2000)
J Natl Cancer Inst 92, 987-994
   Abstract »    Full Text »    PDF »
ErbB2 Immune Response in Breast Cancer Patients with Soluble Receptor Ectodomain.
V. Visco, R. Bei, E. Moriconi, W. Gianni, M. H. Kraus, and R. Muraro (2000)
Am. J. Pathol. 156, 1417-1424
   Abstract »    Full Text »    PDF »
Cooperative Signaling between alpha 6beta 4 Integrin and ErbB-2 Receptor Is Required to Promote Phosphatidylinositol 3-Kinase-dependent Invasion.
D. Gambaletta, A. Marchetti, L. Benedetti, A. M. Mercurio, A. Sacchi, and R. Falcioni (2000)
J. Biol. Chem. 275, 10604-10610
   Abstract »    Full Text »    PDF »
Blocking HER-2/HER-3 Function with a Dominant Negative Form of HER-3 in Cells Stimulated by Heregulin and in Breast Cancer Cells with HER-2 Gene Amplification.
T. G. Ram, M. E. Schelling, and H. L. Hosick (2000)
Cell Growth Differ. 11, 173-183
   Abstract »    Full Text »
Characterization of a Repressor Element and a Juxtaposed Tissue-restricted Activator Element Located on the Distal neu Gene Promoter.
T.-C. Suen and P. E. Goss (2000)
J. Biol. Chem. 275, 6600-6607
   Abstract »    Full Text »    PDF »
ErbB2 Is Necessary for Induction of Carcinoma Cell Invasion by ErbB Family Receptor Tyrosine Kinases.
K. S.R. Spencer, D. Graus-Porta, J. Leng, N. E. Hynes, and R. L. Klemke (2000)
J. Cell Biol. 148, 385-397
   Abstract